Skip to content

Study on the Mechanism of the Role of Macrophage Exosomes in the Development of Rheumatoid Arthritis

Study on the Mechanism of the Role of Macrophage Exosomes in the Development of Rheumatoid Arthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200064042
Enrollment
Unknown
Registered
2022-09-24
Start date
2022-09-24
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Observation Group:None
Healthy control group:None

Sponsors

Tianjin Medical University General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Subjects must meet the 2010 ACR/EULAR rheumatoid arthritis classification criteria and also meet the following inclusion criteria. a. Age >18 years, <80 years, regardless of gender; b. Consent to use effective contraception for the duration of the study (women of childbearing age). c. Patients voluntarily participating in this trial, with the ability to understand and sign an informed consent form prior to the study. d. First diagnosis, moderate-high disease activity (DAS28/CDAI/SDAI), initial treatment recipients. e. No use of hormones, immunosuppressive agents, biologics, etc. at the time of screening.

Exclusion criteria

Exclusion criteria: a. Comorbidity with other rheumatic diseases; b. Combination of other diseases that may cause inflammation of the joints; c. Combination of tumors; d. Those with severe cardiac, hepatic, renal, and other important organ and hematologic and endocrine system pathologies are evaluated according to the following criteria. ? Liver function = 2 times the upper limit of normal value ? Creatinine = 1.5 times the upper limit of normal value ? white blood cell count <3×109/L ? Hemoglobin <80g/L ? Platelet count <60×109/L e. Those who are undergoing acute or chronic infection, or have a previous history of active tuberculosis; f. Those with a history of immunodeficiency, including a positive HIV test, or with other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; g. Positive HBsAb or HCV antibody; h. Those with psychiatric disorders or otherwise unable to cooperate; i. Participating in other clinical trials in the last 3 months; j. Otherwise unsuitable by the investigator;

Design outcomes

Primary

MeasureTime frame
Erythrocyte Sedimentation Rate;C-reactive Protein;DAS28;IL-6;TNF-a;MCP-1;

Countries

China

Contacts

Public ContactXin Lin
limbourg@163.com13302123520

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026